- Giant Invasive Sacral Schwannoma Showing Chromosomal Numerical Aberrations [-14,+18,+22]
-
Kanamori M, Yasuda T, Hori T, Suzuki K
- KMID: 2270437
- Asian Spine J.
- 2013 Sep;7(3):227-231.
- doi: 10.4184/asj.2013.7.3.227
Here, we report on a rare case of a giant invasive sacral schwannoma. The patient was a 58-year-old woman who had a 6-year history of non-specific buttock pain. Histological investigation... -
- CITED
-
- Close
- SHARE
-
- Close
- Minimum 10-Year Follow-up Study of Anterior Lumbar Interbody Fusion for Degenerative Spondylolisthesis: Progressive Pattern of the Adjacent Disc Degeneration
-
Kanamori M, Yasuda T, Hori T, Suzuki K, Kawaguchi
- KMID: 1743281
- Asian Spine J.
- 2012 Jun;6(2):105-114.
- doi: 10.4184/asj.2012.6.2.105
STUDY DESIGN: Retrospective study. PURPOSE: The aims of the current study are to evaluate the minimum 10-year follow-up clinical results of anterior lumbar interbody fusion (ALIF) for degenerative spondylolisthesis. OVERVIEW OF LITERATURE:... -
- CITED
-
- Close
- SHARE
-
- Close
- Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
-
Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T
- KMID: 2512105
- Intest Res.
- 2021 Jan;19(1):95-105.
- doi: 10.5217/ir.2019.09167
Background/Aims: Vedolizumab is indicated for moderately-to-severely active ulcerative colitis (UC) and Crohn’s disease (CD). Because multiple factors may result in different pharmacokinetics and clinical efficacies, understanding determinants of vedolizumab clearance... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
-
Kobayashi T, Ito H, Ashida T, Yokoyama T, Nagahori M, Inaba T, Shikamura M, Yamaguchi T, Hori T, Pinton P, Watanabe M, Hibi T
- KMID: 2521608
- Intest Res.
- 2021 Oct;19(4):448-460.
- doi: 10.5217/ir.2020.00026
Background/Aims: A subgroup analysis was conducted in Japanese patients with moderate to severe ulcerative colitis (UC) enrolled in the phase 3 VISIBLE 1 study, which evaluated the safety and efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
